{"disease":{"id":"chronic-myeloid-leukemia-cml-acute-lymphoblastic-leukemia-all","name":"chronic myeloid leukemia cml acute lymphoblastic leukemia all"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03678454","title":"Iclusig® (Ponatinib) in Clinical Practice for the Treatment of Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia in Belgium","phase":"","overall_status":"COMPLETED","enrollment_count":80,"lead_sponsor_name":"Incyte Biosciences Benelux","has_results":false},{"nct_id":"NCT03595917","title":"ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Marlise Luskin, MD","has_results":false},{"nct_id":"NCT01667133","title":"A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":35,"lead_sponsor_name":"Ariad Pharmaceuticals","has_results":true},{"nct_id":"NCT01592136","title":"Expanded Access Program of Ponatinib","phase":"","overall_status":"APPROVED_FOR_MARKETING","enrollment_count":null,"lead_sponsor_name":"Ariad Pharmaceuticals","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}